The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 27, 2024
Filed:
Dec. 14, 2018
Abl Bio Inc., Seongnam-si, KR;
Jinhyung Ahn, Seongnam-si, KR;
Sungwon An, Seongnam-si, KR;
Dongin Kim, Seongnam-si, KR;
Eunsil Sung, Seongnam-si, KR;
Jaehyun Eom, Seongnam-si, KR;
Sang Hoon Lee, Seongnam-si, KR;
Weonkyoo You, Seongnam-si, KR;
Juhee Kim, Seongnam-si, KR;
Kyungjin Park, Seongnam-si, KR;
Hyejin Chung, Seongnam-si, KR;
Jinwon Jung, Seongnam-si, KR;
Bora Lee, Seongnam-si, KR;
Byungje Sung, Seongnam-si, KR;
Yeunju Kim, Seongnam-si, KR;
Yong-Gyu Son, Seongnam-si, KR;
Seawon Ahn, Seongnam-si, KR;
Daehae Song, Seongnam-si, KR;
Jiseon Yoo, Seongnam-si, KR;
Youngdon Pak, Seongnam-si, KR;
Donghoon Yeom, Seongnam-si, KR;
Yoseob Lee, Seongnam-si, KR;
Jaeho Jung, Seongnam-si, KR;
ABL BIO INC., Seongnam-si, KR;
Abstract
The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.